Pembrolizumab + Platinum Doublets Without Radiation for Programmed Death-ligand 1 (PD-L1) ≥50% Locally Advanced NSCLC

NCT04153734 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

21

Enrollment

OTHER

Sponsor class

Conditions

Locally Advanced Non-small Cell Lung Cancer

Interventions

DRUG: Pembrolizumab
DRUG: Cis Platinum
DRUG: Carboplatin
DRUG: Pemetrexed
DRUG: nab paclitaxel

Sponsor

Kobe Minimally Invasive Cancer Center

Collaborators

[object Object]